VAXCYTE
(NASDAQ: PCVX)

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

108.226

+1.876 (+1.76%)
Range 106.515 - 109.300   (2.61%)
Open 106.760
Previous Close 106.350
Bid Price 50.150
Bid Volume 9
Ask Price 52.770
Ask Volume 10
Volume 73,191
Value -
Remark
Delayed prices. Updated at 01 Nov 2024 22:31.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis